Close Menu

NEW YORK — Predictive Oncology said on Friday that it has signed a letter of intent to acquire biomedical analytics and computational biology firm Quantitative Medicine (QM).

Terms of the acquisition, which is expected to close in the first half of the year, were not disclosed.

According to Predictive Oncology, QM has developed a computational drug discovery platform, called Core, that can predict the main effects of drugs on disease-associated targets.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.